| P2093 | author name string | Changsu Han | |
| | Chi-Un Pae | |
| | Sheng-Min Wang | |
| | Soo-Jung Lee | |
| | Tae-Youn Jun | |
| P2860 | cites work | Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study | Q48082082 |
| | Criticisms of drugs in early development for the treatment of depression: what can be improved? | Q48148268 |
| | Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study | Q48165057 |
| | Agomelatine: a new option for treatment of depression? | Q48375336 |
| | Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). | Q48420974 |
| | Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects | Q48464148 |
| | Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). | Q48555093 |
| | A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). | Q48742900 |
| | Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study | Q48835598 |
| | Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 |
| | Antipsychotics as antidepressants: what is the mechanism? | Q26995363 |
| | Pain and depression: a neurobiological perspective of their relationship | Q28081471 |
| | Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone | Q28201146 |
| | A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder | Q28245017 |
| | Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 | Q28300073 |
| | Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents | Q28307397 |
| | The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) | Q29547223 |
| | Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 |
| | Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 |
| | Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 |
| | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder | Q31121208 |
| | How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins | Q33346867 |
| | Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data | Q33799660 |
| | The epidemiology of depression across cultures | Q33908984 |
| | Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians | Q33910129 |
| | The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. | Q34004814 |
| | Distinctive Clinical Correlates of Psychotic Major Depression: The CRESCEND Study | Q34012235 |
| | Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. | Q34018482 |
| | Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder | Q34027230 |
| | Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. | Q34088016 |
| | Desvenlafaxine in the treatment of major depressive disorder | Q34234091 |
| | Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. | Q34301067 |
| | A review of current evidence for vilazodone in major depressive disorder | Q34338647 |
| | Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. | Q34386877 |
| | Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis | Q34470723 |
| | Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis | Q34473982 |
| | A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. | Q50741608 |
| | Antidepressant specificity in atypical depression. | Q51190598 |
| | Efficacy of aripiprazole in comorbid addiction in bipolar disorder. | Q52300641 |
| | Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. | Q54066721 |
| | Number Needed to Treat: What It Is and What It Isn’t, and Why Every Clinician Should Know How to Calculate It | Q56790907 |
| | Successful use of Aripiprazole for Delusional Disorder with Comorbid Pituitary Microadenoma: A Case Report | Q60473634 |
| | Acceptability of second-step treatments to depressed outpatients: a STAR*D report | Q64111530 |
| | Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia | Q73235980 |
| | Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association | Q73682867 |
| | Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese | Q74380577 |
| | Aripiprazole augmentation for treatment of patients with inadequate antidepressants response | Q79366637 |
| | Do we need more than one antidepressant for patients with major depressive disorder? | Q82114698 |
| | Desvenlafaxine: a new antidepressant or just another one? | Q83620734 |
| | A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises | Q34476432 |
| | Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation | Q34568196 |
| | Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines | Q34590507 |
| | Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy | Q34629315 |
| | Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study | Q34660883 |
| | Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor | Q34769666 |
| | Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 |
| | Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study | Q35043843 |
| | Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. | Q35142087 |
| | Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action | Q35330385 |
| | The Relationship between Depression, Anxiety, Somatization, Personality and Symptoms of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia | Q35330693 |
| | Psychiatric symptoms in temporal lobe epilepsy with left mesial hippocampal sclerosis | Q35330714 |
| | Evidence-based treatment for depressive disorder | Q35330737 |
| | Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder | Q35536869 |
| | Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression | Q35602002 |
| | Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. | Q36635029 |
| | Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials | Q36755314 |
| | Treating depression with atypical features | Q36755712 |
| | Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study | Q36832408 |
| | Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis | Q37007525 |
| | Augmentation of antidepressants with atypical antipsychotics: a review of the current literature | Q37062820 |
| | Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies | Q37101731 |
| | Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence | Q37133284 |
| | Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression | Q37459431 |
| | Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study | Q37696215 |
| | Quetiapine XR: current status for the treatment of major depressive disorder | Q37716089 |
| | Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed | Q37777006 |
| | A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder | Q37795302 |
| | If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies | Q37822778 |
| | Use of risperidone as augmentation treatment for major depressive disorder | Q37824372 |
| | Antidepressant combinations: widely used, but far from empirically validated | Q37901099 |
| | Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression | Q37917092 |
| | Clinical issues in use of atypical antipsychotics for depressed patients | Q38109591 |
| | Management of chronic depressive patients with residual symptoms. | Q38109593 |
| | Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. | Q38125219 |
| | Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan | Q38323149 |
| | Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. | Q38383840 |
| | Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis | Q38417760 |
| | Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response | Q38462018 |
| | Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial | Q38484092 |
| | Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants | Q39304379 |
| | Early switch strategy in patients with major depressive disorder | Q39533915 |
| | Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause | Q40012044 |
| | What predicts attrition in second step medication treatments for depression?: a STAR*D Report. | Q40073042 |
| | Serotonin receptor activation leads to neurite outgrowth and neuronal survival | Q40415290 |
| | What are the comparative benefits and harms of augmentation treatments in major depression? | Q41004704 |
| | A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder | Q42680831 |
| | Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial | Q42928152 |
| | Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies | Q43298201 |
| | Combination antidepressant therapy for major depressive disorder: speed and probability of remission | Q43681255 |
| | Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder | Q43873455 |
| | A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine | Q43873749 |
| | Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression | Q43916260 |
| | Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation | Q43974713 |
| | Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study | Q44020929 |
| | Do atypical features affect outcome in depressed outpatients treated with citalopram? | Q44075173 |
| | 5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus | Q44207406 |
| | A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes | Q44214684 |
| | The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study | Q44627462 |
| | Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study | Q44650956 |
| | Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting | Q44995107 |
| | Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. | Q45208467 |
| | Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study | Q45733394 |
| | STAR*D: revising conventional wisdom. | Q45931500 |
| | Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation | Q46062036 |
| | Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy | Q46315922 |
| | Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. | Q46825728 |
| | A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia | Q46826909 |
| | Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches | Q46963926 |
| | The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial | Q47239632 |
| | Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D. | Q48075779 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | major depressive disorder | Q42844 |
| P304 | page(s) | 66-80 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | Chonnam Medical Journal | Q26842647 |
| P1476 | title | Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice | |
| P478 | volume | 51 | |